Paul Stoffels joined Galapagos as Chief Executive Officer in April 2022, and is an executive member and the Chairman of our Board of Directors since 26 April 2022. He also is a member of the Executive Committee at Galapagos. Prior to that, he was Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson where he set the company’s wide innovation agenda and led its pharmaceutical R&D-pipeline, as well as other external initiatives. Before that, he was worldwide Chairman of Pharmaceuticals of Johnson & Johnson which, under his leadership, significantly rejuvenated its product pipeline and adopted a transformational R&D-operating model, which resulted in the launch of 25 innovative medicines across the globe. Dr. Stoffels joined Johnson & Johnson in 2002, following the acquisition of Virco and Tibotec, where he was Chief Executive Officer and Chairman respectively, and where he led the development of several breakthrough products for the treatment of HIV. Dr. Stoffels also is a member of the Supervisory Board of Philips Healthcare in the Netherlands.
Paul Stoffels is contributing to the following courses
Clinical Product Development
Clinical product development plays a key role in bringing new products to market and patients. Gain expertise in determining safe and informative starting doses using NOAEL and MABEL approaches, and learn product development through real-world case studies.
Clinical product development plays a key role in bringing new products to market and patients. Gain expertise in determining safe and informative starting doses using NOAEL and MABEL approaches, and learn product development through real-world case studies.
Clinical product development plays a key role in bringing new products to market and patients. Gain expertise in determining safe and informative starting doses using NOAEL and MABEL approaches, and learn product development through real-world case studies.
A global healthcare executive, Piet Hinoul, M.D., Ph.D., brings 30 years of healthcare experience to Virtual Incision, of which the past 15 have been spent in the medtech industry. In his past roles, Piet has served as Senior V.P., Global Head Medical Affairs at Novocure, and V.P., Global Head for Medical, Clinical, and Pre-Clinical Affairs for the surgical subsidiary of Johnson & Johnson, Ethicon. Piet is a European Board-certified gynecologist whose work has been published extensively on various surgery topics and who has lectured internationally throughout his career on the fields of urogynecology, surgery, and medical device innovation. Piet earned his M.D. from the University of Leuven, and his Ph.D. in biomedical sciences from the University of Amsterdam.
Company ClinPharMed Consultancy for Drug Development
Function Owner
Prof. Dr J.M. Ad Sitsen completed his pharmaceutical studies at the State University of Utrecht in The Netherlands in March 1970 and obtained a Ph.D. in medicinal chemistry two years later. After having fulfilled his compulsory military service with the Royal Dutch Navy he began his medical studies in 1974, which he completed in 1980. He then specialized in pharmacology at the Rudolf Magnus Institute of the Medical Faculty of the University of Utrecht and subsequently trained for two years in internal medicine at the Academic Hospital of the same Medical Faculty.
In 1984 he joined N.V. Organon, a business unit of Akzo Nobel, and has been involved in the clinical development of Remeron® from the beginning and also many other compounds. He retired in 2004 and now acts as a consultant to pharmaceutical companies.
He was a member of the Dutch Health Council and a (part-time) professor of clinical pharmacology at the Medical Faculty of the Utrecht University, Utrecht, The Netherlands.
He has published approximately 100 research articles and reports and was editor of volume 6 of the Handbook of Sexology: The Pharmacology and Endocrinology of Sexual Function (Amsterdam:Elsevier, 1988). He is co-editor of the Handbook of Anxiety and Depression: A biological Approach (New York: Marcel Dekker, 1994) and editor-in-chief of the major Dutch language textbook of pharmacology.
Specialties: assessment of toxicological data, design of first time in man studies, clinical pharmacology, drug development, medical writing
Marcel Kenter studied molecular biology at Leiden University and obtained his PhD degree for his work on the genetics of the primate Major Histocompatibility Complex (Mhc) in the immunology department of Prof Johannes van Rood (Leiden University Medical Center (LUMC), the Netherlands). He continued his post-doctoral work on virology at the department of Prof. Ab Osterhaus (Erasmus Medical Center, the Netherlands) and on gene therapy at the Daniel den Hoed Cancer Center. In 1999, he became the first executive director of the Central Committee Involving Human Subjects (CCMO); the competent authority for clinical trials with medicinal products in the Netherlands. He has been director of Paul Janssen Futurelab Leiden since 2015.
Function VP Scientific Fellow Infectious Diseases Discovery
Dr Koen Andries (1951) studied Veterinary Sciences and obtained his PhD at the University of Ghent, Belgium. He joined the team of Dr. Paul Janssen in 1982. Using cell-based assays in search of antiviral compounds, his team discovered nanomolar inhibitors of uncoating of rhinoviruses, picomolar inhibitors of fusion of respiratory syncytial virus and several non-nucleoside reverse transcriptase inhibitors of HIV (TIBO’s, alpha-APA’s, and DAPY’s) with high activity against wild-type and resistant HIV-1 strains. Two of these became approved drugs: etravirine - intelence® and rilpivir - edurant®, and a third one is being developed as a microbicide in a vaginal ring to prevent HIV infection (dapivirine).
Dr Andries also led the team that discovered R207910/TMC207 (bedaquiline – sirturo®), a first in-class new anti-tuberculosis drug, and its unique mechanism of action. Bedaquiline is the first molecule with specific activity against the ATP synthase, one of the most fundamental enzymes in biology, and the first antibiotic known to interfere with the generation of energy. He grandfathered bedaquiline from discovery to early development and eventually full development as the microbiology leader. He authors 173 papers, 179 abstracts and 32 patents, and is Professor emeritus at the University of Antwerp.
I am a physician with a neurological and methodological background (clinical epidemiologist). Since 1992 I work as a senior clinical assessor at the Dutch Medicines Evaluation Board. As a clinical assessor I advice the Dutch Medicines Evaluation Board and the European Committee for Proprietary Medicinal Products whether a medicinal agent may be approved for a claimed indication and if so, under which conditions. The MEB I started as a generalist but may main field of interest is neurology. In this context I am member of the CNS-Working party involved in setting up regulatory Scientific Guidelines. Within the neurology my special fields of interest are Multiple sclerosis, Parkinson's Disease and Epilepsy. As generalist I became member of the Scientific Advice Working party in 2012.
Function Former Senior Vice President and Chief Scientific, Clinical and Regulatory Officer
Dr. Rick Kuntz was Medtronic’s Senior Vice President, Chief Medical and Scientific Officer of Medtronic and served as a member of the Company’s Executive Committee until 2021. In this role, Kuntz oversaw the company’s medical affairs, health policy and reimbursement, clinical research activities, and corporate technology.
